Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Allergy Clin Immunol. 2011 Sep 8;128(5):977–82.e1-2. doi: 10.1016/j.jaci.2011.07.018

Table 2.

Occurrence and severity of cough and wheeze scores preceding NASRA

2a. Occurrence and severity of cough during the day preceding a NASRA
Report of NASRA that night
Cough score during day No NASRA
n (%)
NASRA
n (%)
0 (no symptoms) 57080 (98.6) 802 (1.4) P<0.0001
1 (mild) 14635 (96.4) 540 (3.5)
2 (moderate) 3414 (87.8) 477 (12.3)
3 (severe) 592 (81.0) 141 (19.0)
2b. Occurrence and severity of wheeze during the day preceding a NASRA
Report of NASRA that night
Wheeze score during day No NASRA
n (%)
NASRA
n (%)
0 (no symptoms) 65719 (98.3) 1170 (1.7) P<0.0001
1 (mild) 7607 (94.4) 448 (5.6)
2 (moderate) 2114 (88.3) 281 (11.7)
3 (severe) 281 (82.2) 61 (17.8)
2c. Occurrence and amount of albuterol use during the day preceding a NASRA
Report of NASRA that night
Puffs of albuterol in
previous 24 hours
No NASRA
n (%)
NASRA
n (%)
0 61020 (98.6) 851 (1.4) P<0.0001
1–2 9663 (95.0) 499 (5.0)
3–4 3296 (91.9) 291 (8.1)
5–6 1006 (88.6) 129 (11.4)
≥7 736 (79.5) 190 (20.5)
2d. Evening PEF and the occurrence of a NASRA that night
Report of NASRA that night
PM PEF Zone No NASR
n (%)
NASRA
n (%)
Green 60259 (98.6) 858 (1.4) P<0.0001
Yellow 10680 (96.1) 437 (3.9)
Red 286 (94.1) 18 (5.9)

n=number of events for all participants